Mylvaganam RJ, Joseph I, Bailey JI, Sznajder JI, Sala MA, on behalf of the Northwestern Comprehensive COVID Center Consortium. Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection. Eur Respir Rev 2021;30:210194.
Ambardar SR, Hightower SL, Huprikar NA, Chung KK, Singhal A, Collen JF. Post-COVID-19 pulmonary fibrosis: novel sequelae of the current pandemic. J Clin Med 2021;10:2452. https://doi.org/10.3390/jcm10112452 https://www.mdpi.com/journal/jcm
Michalski JA, Kurche JS, Schwartz DA. From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic? Transl Res 2021; doi: 10.1016/j.trsl.2021.09.001
Lerum TV, Aalokken TM, Bronstad E, Aarli B, Ikdah E, Lund KMA, et al. Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19. Eur Respir J 2021;57:2003448.
Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology 2021;299:E177–E186.
Zhao YM, Shang YM, Song WB, Li Q, Xi H, Xu Q, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. E Clin Med 2020;25:100463.
Udwadia ZF, Koul PA, Richeldi L. Post-COVID lung fibrosis: the tsunami that will follow the earthquake. Lung India 2021;38:S41–7.
Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open 2021;4:e210830.20.
Bazdyrev E, Rusina P, Panova M, Novikov F, Grishagin I, Nebolsin V. Lung fibrosis after COVID-19: treatment prospects. Pharmaceuticals 2021;14:807. https://doi.org/10.3390/ph14080807.
Guler SA, Ebner L, Aubry-Beigelman C, Bridevaux PO, Brutsche M, Clarenbach C, et al. Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. Eur Respir J 2021;57:2003690.
Kumar R, Behera D, Jindal SK, Menon BK, Goel N, et al. Post-COVID-19 respiratory management: expert panel report. Indian J Chest Dis Allied Sci 2020;62:179–91.
Mohan A, Tiwari P, Bhatnagar S, Patel A, Maurya A, Dar L, et al. Clinico-demographic profile and hospital outcomes of COVID-19 patients admitted at a tertiary care centre in north India. Indian J Med Res 2020;152:61–69.
Crisan-Dabija R, Pavel VCA, Popa VIV, Andrei Tarus A, Burlacu A. “A chain only as strong as its weakest link”: an up-to-date literature review on the bidirectional interaction of pulmonary fibrosis and COVID-19. J Proteome Res 2020;19:4327−38.
Chang YC, Yu CJ, Chang SC, Galvin JR, Liu HM, Hsiao CH, et al. Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin section CT. Radiology 2005;236:1067–75.
Bharat A, Machuca TN, Querrey M, Kurihara C, Garza-Castillon R, Kim S Jr, et al. Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. Lancet Respir Med 2021;9:487–97.
King CS, Mannem H, Kukreja J, Aryal S, Tang D, Singer JP, et al. Lung transplantation of COVID-19 patients.Chest 2021;9 doi: 10.1016/j.chest.2021.08.041
Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021;384:693–704.
George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID 19: the potential role for antifibrotic therapy. Lancet Resp Med 2020;8:807–15.
Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: anti inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol 2020;76:1615–8.
Umemuraa Y, Mitsuyamaa Y, Minamia K, Nishidaa T, Watanabea A, Okadac N, et al. Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: an interventional study. Inter Jour Infect Dis 2021;108:454–60.
Chaudhary S, Natt B, Bime C, Knox KS, Glassberg MK. Antifibrotics in COVID-19 lung disease: let us stay focused. Front Med (Lausanne) 2020;7:539.
Hsieh MJ, Lee WC, Cho HY, Wu MF, Hu HC, Kao KC, et al. Recovery of pulmonary functions, exercise capacity, and quality of life after pulmonary rehabilitation in survivors of ARDS due to severe influenza A (H1N1) pneumonitis. Influenza Other Respir Viruses 2018;12:643–8.
